830 WINTER STREET, WALTHAM, MA
Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Q32 Bio Inc. Enters Underwriting Agreement for 6M Shares at $18.25 Each
Investor Presentation
Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
Announces $55 Million Private Placement Financing
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Annual Report to Security Holders
Q32 Bio Inc. Enters Controlled Equity Offering Sales Agreement for $14.2M
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Amended Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence
Post-Effective Amendment to Registration Statement